{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:47:32Z","timestamp":1782838052884,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jcf.2020.03.019","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T09:34:15Z","timestamp":1587375255000},"page":"949-954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Penetrance is a critical parameter for assessing the disease liability of CFTR variants"],"prefix":"10.1016","volume":"19","author":[{"given":"A.","family":"Boussaroque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-P.","family":"Audr\u00e9zet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Raynal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"F\u00e9rec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bergougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Scotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Munck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7913-4682","authenticated-orcid":false,"given":"E.","family":"Girodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Dec (6","key":"10.1016\/j.jcf.2020.03.019_bib0001","first-page":"701","article-title":"Cystic fibrosis diagnosis in newborns, children, and adults","volume":"40","author":"Castellani","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"Apr 20 (2","key":"10.1016\/j.jcf.2020.03.019_bib0002","article-title":"Early diagnosis from newborn screening maximises survival in severe cystic fibrosis","volume":"4","author":"Tridello","year":"2018","journal-title":"ERJ Open Res"},{"issue":"Mar (2","key":"10.1016\/j.jcf.2020.03.019_bib0003","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jcf.2016.12.012","article-title":"The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe","volume":"16","author":"Barben","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"Feb","key":"10.1016\/j.jcf.2020.03.019_bib0004","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"Dec (6","key":"10.1016\/j.jcf.2020.03.019_bib0005","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1542\/peds.2015-0811","article-title":"California cystic fibrosis newborn screening consortium. Newborn screening for cystic fibrosis in California","volume":"136","author":"Kharrazi","year":"2015","journal-title":"Pediatrics"},{"issue":"May (3","key":"10.1016\/j.jcf.2020.03.019_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"Feb","key":"10.1016\/j.jcf.2020.03.019_bib0007","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jpeds.2016.09.063","article-title":"Applying cystic fibrosis transmembrane conductance regulator genetics and CFTR2 data to facilitate diagnoses","volume":"181S","author":"Sosnay","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2020.03.019_bib0008","series-title":"Johns hopkins university, the hospital for sick children","year":"2019"},{"issue":"Oct (10","key":"10.1016\/j.jcf.2020.03.019_bib0009","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/humu.23276","article-title":"CFTR -France, a national relational patient database for sharing genetic and phenotypic data associated with rare CFTR variants","volume":"38","author":"Claustres","year":"2017","journal-title":"Hum Mutat"},{"issue":"Nov (11","key":"10.1016\/j.jcf.2020.03.019_bib0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/jmg.2009.067215","article-title":"Roussey M; Collaborating Working Group on R117H, Girodon E. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening","volume":"46","author":"Thauvin-Robinet","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.jcf.2020.03.019_bib0011","article-title":"Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes","author":"Karczewski","year":"2019","journal-title":"In BioRxiv"},{"issue":"Feb (2","key":"10.1016\/j.jcf.2020.03.019_bib0012","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/gim.2014.113","article-title":"Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy","volume":"17","author":"Audr\u00e9zet","year":"2015","journal-title":"Genet Med"},{"issue":"Mar (1","key":"10.1016\/j.jcf.2020.03.019_bib0013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0969141317692611","article-title":"Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process","volume":"25","author":"Munck","year":"2018","journal-title":"J Med Screen"},{"key":"10.1016\/j.jcf.2020.03.019_bib0014","unstructured":"Rapports d'activit\u00e9 m\u00e9dicale et scientifique de l'Agence de la biom\u00e9decine, diagnostic pr\u00e9natal par g\u00e9n\u00e9tique mol\u00e9culaire. 2007\u20132017. Available at: https:\/\/rams.agence-biomedecine.fr\/diagnostic-sur-lembryon-et-le-foetus."},{"issue":"May (5","key":"10.1016\/j.jcf.2020.03.019_bib0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"Jun 2 (6","key":"10.1016\/j.jcf.2020.03.019_bib0016","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ajhg.2016.03.024","article-title":"Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium","volume":"98","author":"Amendola","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"Mar 11 (6416","key":"10.1016\/j.jcf.2020.03.019_bib0017","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/362160a0","article-title":"Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties","volume":"362","author":"Sheppard","year":"1993","journal-title":"Nature"},{"issue":"Jan (1","key":"10.1016\/j.jcf.2020.03.019_bib0018","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1086\/381001","article-title":"Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign","volume":"74","author":"Groman","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"Oct (10","key":"10.1016\/j.jcf.2020.03.019_bib0019","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat Genet"},{"issue":"Apr (4","key":"10.1016\/j.jcf.2020.03.019_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1399-0004.2009.01294.x","article-title":"Non-classic cystic fibrosis associated with D1152H CFTR mutation","volume":"77","author":"Burgel","year":"2010","journal-title":"Clin Genet"},{"issue":"Feb","key":"10.1016\/j.jcf.2020.03.019_bib0021","first-page":"S45","article-title":"Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive","volume":"181S","author":"Ren","year":"2017","journal-title":"Inconclusive Diagnosis. J Pediatr."},{"issue":"Dec (12","key":"10.1016\/j.jcf.2020.03.019_bib0022","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.arcped.2017.07.015","article-title":"Guidelines for the clinical management and follow-up of infants with inconclusive cystic fibrosis diagnosis through newborn screening","volume":"24","author":"Sermet-Gaudelus","year":"2017","journal-title":"Arch Pediatr"},{"issue":"Jan 3(1","key":"10.1016\/j.jcf.2020.03.019_bib0023","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ajhg.2018.11.016","article-title":"BabySeq project team. interpretation of genomic sequencing results in healthy and ill newborns: results from the Babyseq project","volume":"104","author":"Ceyhan-Birsoy","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"Mar (3","key":"10.1016\/j.jcf.2020.03.019_bib0024","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/gim.2015.172","article-title":"Newborn testing and screening by whole-genome sequencing","volume":"18","author":"Kingsmore","year":"2016","journal-title":"Genet Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320300989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320300989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:42:29Z","timestamp":1761601349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199320300989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1569199320300989"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.03.019","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Penetrance is a critical parameter for assessing the disease liability of CFTR variants","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}